For US healthcare professionals only.
For US healthcare professionals only.

Important Safety Information:

CONTRAINDICATIONS: ELOCTATE® is contraindicated in patients who have had life-threatening hypersensitivity reactions to ELOCTATE or its excipients.

WARNINGS AND PRECAUTIONS: Hypersensitivity reactions have been reported with ELOCTATE. Allergic-type hypersensitivity reactions, including anaphylaxis, have been reported with Factor VIII replacement products. View more


Support and Resources

Sanofi is proud to offer financial programs and resources to help your patients minimize their out-of-pocket costs for ELOCTATE®

We offer three programs:

  • Calendar Icon

    Free Trial Plus Program*

    Patients get their first 30-day supply of treatment within 24-48 hours with a valid prescription. While you and the patient are deciding what treatment is right for them, a dedicated Sanofi professional will review their health insurance information and coverage for ELOCTATE.

    Enroll patients online, and a dedicated Sanofi professional will contact them within 24 hours.

    DOWNLOAD FORM
  • Search with $ Icon

    Copay Program*

    Patients pay as little as $0 with maximum annual saving up to $20,000 with no income caps.

    Enroll eligible patients online or by contacting a dedicated Sanofi professional at 1-855-MyELOCTATE

    LEARN MORE
  • Factor Access Program Icon

    Factor Access Program*

    Patients can access treatment even if their insurance is interrupted. Available to eligible patients with no income caps.

    Enroll patients online, and a dedicated Sanofi professional will contact them within 24 hours.

    DOWNLOAD FORM

Questions? Call 1-855-MyELOCTATE (1-855-693-5628), Monday through Friday,
8 AM to 8 PM ET, or request a visit with an ELOCTATE representative.

* Copay Program not valid for patients utilizing Medicare, Medicaid, VA, DoD, TRICARE®️, or similar federal or state programs including any state pharmaceutical assistance programs to pay in part or full for their prescriptions. Savings may vary depending on patients’ out of pocket costs. Free trial Plus valid only for a patient’s first prescriptions and it is limited to one use per patient per product for their lifetime. Free products dispensed through the Free Trial Plus or Factor Access Programs shall not be submitted to any third-party payer, public or private (e.g. private insurance, Medicaid, Medicare, VA, DoD, TRICARE, or similar federal or state programs) for reimbursement. All Programs not valid were prohibited by law. Sanofi reserves the right to modify or terminate the Programs at any time without notice. Program details provided upon registration.

Access additional resources for your patients

Conversation Starter Guide

This guide contains a series of questions designed to help patients determine what’s important in their hemophilia A treatment.

DOWNLOAD GUIDE
EN ESPAÑOL

Doctor Discussion Guide

This guide can help your patients prepare to have a more productive conversation about their hemophilia A treatment options and determine if ELOCTATE is right for them.

DOWNLOAD GUIDE

The Count On Prospect Brochure

From data to real life patient stories, this guide offers additional information and support on ELOCTATE to help your patients navigate their hemophilia A treatment journey.

DOWNLOAD GUIDE
EN ESPAÑOL

Keep track of hemophilia with MicroHealth

Download the App

MicroHealth app

Sanofi has joined with MicroHealth in supporting patients and healthcare providers to better manage hemophilia.

Learn more

MicroHealth app

Apple and the Apple logo are trademarks of Apple Inc. App Store is a service mark of Apple Inc.

Google Play and the Google Play logo are trademarks of Google LLC.

MicroHealth Brochure

Get details about how to set up an account for your practice to help monitor and support your patients on ELOCTATE. Help keep them on track and stay connected via mobile and web apps.

DOWNLOAD BROCHURE
 

Free laboratory tests for ELOCTATE

Sanofi has contracted with LabCorp (Esoterix) to provide a central lab to perform standardized one-stage clotting assays with a national network of local laboratories for specimen collection at no extra cost for the patient or healthcare provider.

For more information about monitoring with LabCorp, contact your ELOCTATE representative.

 

ELOCTATE billing and coding information

Healthcare providers are responsible for ensuring accurate and appropriate diagnostic coding† to obtain reimbursement. For quick reference, please review the appropriate codes noted below. Learn more about the Sanofi Support Programs available for your patients by calling MyELOCTATE: 1-855-693-5628.

†This information is provided for informational purposes only and does not constitute legal or reimbursement advice. It is not intended to substitute for the physician’s independent diagnosis or treatment of each patient. The information contained herein is gathered from various resources and is subject to change. Providers are solely responsible for the accuracy of all coding and claims submitted for reimbursement to any third-party payor.

ICD-10-CM & HCPCS Codes

ICD-10-CM Diagnosis Code

The following ICD-10-CM code may be used to identify patient medical conditions typically associated with hemophilia A.

ICD-10-CM Code D66

Description Hereditary factor VIII deficiency

 

HCPCS Code

The following represents the drug code for ELOCTATE. The prescriber is advised to verify with the payor or Medicare fiscal intermediary to determine the correct code(s).

HCPCS Code J7205

Description Injection, factor VIII Fc fusion protein (recombinant)

ELOCTATE National Drug Codes (NDCs)
Nominal potency
(IU)		 NDC #
250 71104-0801-01
500 71104-0802-01
750 71104-0803-01
1000 71104-0804-01
1500 71104-0805-01
2000 71104-0806-01
3000 71104-0807-01
4000 71104-0808-01
5000 71104-0809-01
6000 71104-0810-01

Your ELOCTATE® representative can provide additional materials about ELOCTATE for your patients.

Contact your local
ELOCTATE representative

INDICATION
ELOCTATE is a recombinant DNA derived, antihemophilic factor indicated in adults and children with Hemophilia A (congenital Factor VIII deficiency) for: on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.

Limitation of Use

ELOCTATE is not indicated for the treatment of von Willebrand disease.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
ELOCTATE is contraindicated in patients who have had life-threatening hypersensitivity reactions to ELOCTATE or its excipients.

WARNINGS AND PRECAUTIONS

  • Hypersensitivity reactions have been reported with ELOCTATE. Allergic-type hypersensitivity reactions, including anaphylaxis, have been reported with Factor VIII replacement products. Immediately discontinue ELOCTATE and initiate appropriate treatment if hypersensitivity reactions occur.
  • Formation of neutralizing antibodies (inhibitors) to Factor VIII has been reported following administration of ELOCTATE. Patients using ELOCTATE should be monitored for the development of Factor VIII inhibitors. Clotting assays (e.g., one-stage) may be used to confirm that adequate Factor VIII levels have been achieved and maintained.
  • Hemophilic patients with cardiovascular risk factors or diseases may be at the same risk to develop cardiovascular events as non-hemophilic patients when clotting has been normalized by treatment with Factor VIII.
  • If a central venous access device (CVAD) is required, risk of CVAD-related complications including local infections, bacteremia, and catheter-site thrombosis should be considered.

ADVERSE REACTIONS
The most frequently occurring adverse reactions (incidence >0.5% of subjects) reported in previously treated patients (PTPs) clinical trials were arthralgia, malaise, myalgia, headache, and rash. The most frequently occurring adverse reactions (incidence ≥1.0% of subjects) reported in previously untreated patients (PUPs) clinical trials were Factor VIII inhibition, device-related thrombosis, and rash papular.


Please see full Prescribing Information.

Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.

Reference: 1. ELOCTATE [package insert]. Waltham, MA: Bioverativ Therapeutics Inc.

References: 1. Srivastava A et al. Haemophilia. 2013;19(1):e1-e47. 2. Mazepa MA et al. Blood. 2016;127(24):3073-3081.

References: 1. ELOCTATE [package insert]. Waltham, MA: Bioverativ Therapeutics Inc. 2. Mahlangu JN et al. Thromb Haemost. 2016;116:1-8. 3. Shapiro A. Expert Opin Biol Ther. 2013;13(9):1287-1297. 4. Kaneko Y et al. Science. 2006(5787);313:670-673. 5. Kis Toth K et al. Blood Adv. 2018;2(21):2904-2916.

References: 1. ELOCTATE [package insert]. Waltham, MA: Bioverativ Therapeutics Inc. 2. Data on file. Waltham, MA; Bioverativ Therapeutics Inc. 3. Mahlangu JN et al. Thromb Haemost. 2016;116:1-8. 4. Oldenburg J et al. Haemophilia. 2018;24(1):77-84. 5. Young G et al. J Thromb Haemost. 2015;13:1-11. 6. Nolan B et al. Haemophilia. 2016;22:72-80.

Back to the top